NCT04567056|RecruitingDMC
Specific Methylation Profiles in HNSCC
Validation of Specific Methylation Profiles Ind Head and Neck Cancer - a Cohort Study
Loading search results
Validation of Specific Methylation Profiles Ind Head and Neck Cancer - a Cohort Study
Sponsor study identifier
observational
300
1 country
1
Study Start
September 16, 2020
Actual (reported)Primary Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
In the study, N-20190047, the investigators aim to define specific methylation patterns in a group of patients with head and neck squamous cell carcinomas. With this study the investigators aim to validate these findings in a larger cohort.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 16, 2020
Actual (reported)September 23, 2020
Actual (reported)September 28, 2020
Actual (reported)December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Diagnostic accuracy
How accurate can the methylation profiles diagnose the head and neck squamous cell carcinoma
At diagnosis
Patients with verified head and neck squamous cell carcinomas
Matched control group without active or earlier cancer and a normal ENT examination.
A separate blood sample will be taken for methylation-analyses
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cancer group: Patients referred from the region of Northern Denmark to the Department of Otorhinolaryngology - Head and Neck Surgery with suspicion of, or with already verified Head and neck squamous cell carcinoma. Only patients with verified squamous cell carcinoma after diagnostic work-up will be eligible. Control group: Patients referred from the region of Northern Denmark to the Department of Otorhinolaryngology - Head and Neck Surgery for evaluation or treatment, but without suspected or verified malignancy of the head and neck.
Department of Otolaryngology - Head and Neck Surgery
Aalborg, 9000, Denmark
Peripheral blood samples
Michael Gaihede, Professor
Department of Otolaryngology - Head and Neck Surgery, Aalborg University Hospital
Michael Gaihede, Professor
CONTACT
First Submitted
September 23, 2020
First Posted
September 28, 2020
Study Start
September 16, 2020
Actual (reported)Primary Completion
December 31, 2025
Estimated (date passed)Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 7, 2025
Record last verified: 2025-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: